Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand

被引:201
作者
Abe, R [1 ]
Shimizu, T [1 ]
Shibaki, A [1 ]
Nakamura, H [1 ]
Watanabe, H [1 ]
Shimizu, H [1 ]
机构
[1] Hokkaido Univ, Grad Sch Med, Dept Dermatol, Kita Ku, Sapporo, Hokkaido 0608638, Japan
关键词
D O I
10.1016/S0002-9440(10)64284-8
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The pathogeneses of toxic epidermal necrolysis (TEN) and Stevens Johnson syndrome (SJS), both severe blistering diseases usually associated with drug intake, are not fully elucidated. Histologically, both TEN and SJS are characterized by extensive keratinocyte apoptosis. Previous studies have shown that keratinocyte apoptosis in TEN and SJS was induced by a suicidal interaction between Fas and Fas ligand (FastL), which are both expressed by keratinocytes. However, our preliminary examinations demonstrated that FasL is hardly detected on keratinocytes. We hypothesized that soluble FasL (sFasL) is secreted by peripheral blood mononuclear cells (PBMCs), and this interacts with the Fas expressed on keratinocytes in TEN and SJS. To justify this hypothesis, we investigated whether sFasL secreted by PBMCs could induce the keratinocyte apoptosis in TEN and SJS. Enzyme-linked immunosorbent assay analysis demonstrated that there was no significant sFasL increase in any samples of healthy controls (<40 pg/ml, n = 14) and patients with an ordinary erythema multiforme-type drug eruption (41.5 +/- 3.1 pg/ml, n = 14), whereas high concentrations are detected in all samples of TEN and SJS patients (TEN: 131.5 +/- 57.4 pg/ml, n = 8; SJS: 119.1 +/- 41.0 pg/ml, n = 14) (P < 0.0001). In vitro analysis using cultured keratinocytes revealed that the sera of TEN and SJS patients induced abundant keratinocyte apoptosis compared to erythema multiforme-type drug eruption sera. Furthermore, on stimulation with the causal drug, PBMCs obtained from TEN and SJS patients secreted high levels of sFasL. Taken together, these results indicate that sFasL secreted by PBMCs, not keratinocytes, plays a crucial role in the apoptosis and pathomechanism of TEN and SJS, and that the serum sFasL level may be a good indicator for the early diagnosis of TEN and SJS.
引用
收藏
页码:1515 / 1520
页数:6
相关论文
共 26 条
  • [1] CLINICAL CLASSIFICATION OF CASES OF TOXIC EPIDERMAL NECROLYSIS, STEVENS-JOHNSON SYNDROME, AND ERYTHEMA MULTIFORME
    BASTUJIGARIN, S
    RZANY, B
    STERN, RS
    SHEAR, NH
    NALDI, L
    ROUJEAU, JC
    [J]. ARCHIVES OF DERMATOLOGY, 1993, 129 (01) : 92 - 96
  • [2] Toxic epidermal necrolysis
    Becker, DS
    [J]. LANCET, 1998, 351 (9113) : 1417 - 1420
  • [3] CUTANEOUS T-CELL RECRUITMENT IN TOXIC EPIDERMAL NECROLYSIS - FURTHER EVIDENCE OF CD8+ LYMPHOCYTE INVOLVEMENT
    CORREIA, O
    DELGADO, L
    RAMOS, JP
    RESENDE, C
    FLEMING, JA
    [J]. ARCHIVES OF DERMATOLOGY, 1993, 129 (04) : 466 - 468
  • [4] Antitumour necrosis factor-α antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis
    Fischer, M
    Fiedler, E
    Marsch, WC
    Wohlrab, J
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2002, 146 (04) : 707 - 708
  • [5] IDENTIFICATION OF PROGRAMMED CELL-DEATH INSITU VIA SPECIFIC LABELING OF NUCLEAR-DNA FRAGMENTATION
    GAVRIELI, Y
    SHERMAN, Y
    BENSASSON, SA
    [J]. JOURNAL OF CELL BIOLOGY, 1992, 119 (03) : 493 - 501
  • [6] IMPROVED BURN CENTER SURVIVAL OF PATIENTS WITH TOXIC EPIDERMAL NECROLYSIS MANAGED WITHOUT CORTICOSTEROIDS
    HALEBIAN, PH
    CORDER, VJ
    MADDEN, MR
    FINKLESTEIN, JL
    SHIRES, GT
    [J]. ANNALS OF SURGERY, 1986, 204 (05) : 503 - 512
  • [7] TOXIC EPIDERMAL NECROLYSIS TREATED WITH CYCLOSPORINE
    HEWITT, J
    ORMEROD, AD
    [J]. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1992, 17 (04) : 264 - 265
  • [8] IWAI K, 1994, BLOOD, V84, P1201
  • [9] METALLOPROTEINASE-MEDIATED RELEASE OF HUMAN FAS LIGAND
    KAYAGAKI, N
    KAWASAKI, A
    EBATA, T
    OHMOTO, H
    IKEDA, S
    INOUE, S
    YOSHINO, K
    OKUMURA, K
    YAGITA, H
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (06) : 1777 - 1783
  • [10] KELEMEN JJ, 1995, J AM COLL SURGEONS, V180, P273